Clinical Trials on Platinum Sensitive Relapsed Ovarian Cancer

Total 9220 results

National Cancer Institute (NCI)

Recruiting

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

Recurrent Fallopian Tube Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Carcinoma | Stage III Uterine Corpus Cancer AJCC v8 | Stage IV Uterine Corpus Cancer AJCC v8 | Recurrent Platinum-Resistant Ovarian Carcinoma | Metastatic Fallopian Tube Carcinoma | Metastatic Primary... and other conditions

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Active, not recruiting

Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1

Metastatic Melanoma | Advanced Malignant Solid Neoplasm | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Ovarian Seromucinous Carcinoma | Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Fallopian Tube Mucinous Adenocarcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian Tube Endometrioid Adenocarcinoma | Recurrent... and other conditions

United States, Puerto Rico
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Survivorship Care Planning in Improving Quality of Life in Survivors of Ovarian Cancer

Cancer Survivor | Stage IIIA Ovarian Epithelial Cancer | Stage IIIB Ovarian Epithelial Cancer | Stage IIIC Ovarian Epithelial Cancer | Stage IIA Ovarian Epithelial Cancer | Stage IIB Ovarian Epithelial Cancer | Stage IIC Ovarian Epithelial Cancer | Stage IA Ovarian Epithelial Cancer | Stage IB Ovarian... and other conditions

United States
Azienda Ospedaliero-Universitaria Careggi

Not yet recruiting

APalutamiAPalutamide and stEReotactic Body Radiation Therapy for Metastatic Prostate Cancer (PERSIAN)

Oligometastatic Hormone Sensitive Prostate Cancer

Italy
Astellas Pharma Global Development, Inc.

Completed

Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) Study

Prostate Cancer | Metastatic Hormone-sensitive Prostate Cancer

United States
Dr. Patrick Cheung

Withdrawn

Feasibility Trial in Men With Hormone Sensitive Oligometastatic Prostate Cancer (PRORAD)

Hormone Sensitive Oligometastatic Prostate Cancer

Canada
PharmaMar

Completed

Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients (NIMES-ROC)

Relapsed Ovarian Cancer

Spain, France, Italy, Belgium, Germany
SCRI Development Innovations, LLC
GlaxoSmithKline

Terminated

Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Carcinoma

United States
Kindai University
Janssen Pharmaceutical K.K.

Recruiting

Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in Japan (CUARTET)

Metastatic Castration-sensitive Prostate Cancer

Japan
Spanish Oncology Genito-Urinary Group
Bristol-Myers Squibb; Syntax for Science, S.L

Active, not recruiting

A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer

Metastatic Hormone-sensitive Prostate Cancer

Spain
Washington University School of Medicine
Bristol-Myers Squibb; The Foundation for Barnes-Jewish Hospital; Bavarian Nordic and other collaborators

Completed

Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

Metastatic Hormone-Sensitive Prostate Cancer

United States
Peng Wang, MD PhD

Withdrawn

Toxicity & Pharmacokinetics of 2 & 3-weekly Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Metastatic Hormone-Sensitive Prostate Cancer

United States
Stanford University
Susan G. Komen Breast Cancer Foundation; Breast Cancer Research Foundation

Recruiting

Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples

Breast Cancer | Ovarian Cancer | Gynecologic Cancers | Ovarian/Peritoneal/Fallopian Cancer

United States
Leap Therapeutics, Inc.
Pfizer; Merck KGaA, Darmstadt, Germany

Terminated

A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

Solid Tumors | Advanced Triple Negative Breast Cancer | Advanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer | Advanced Metastatic Castration-Resistant Prostate Cancer | Advanced Platinum-Resistant Ovarian Cancer

United States
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients

Relapsed Ovarian Cancer

China
Fudan University

Not yet recruiting

Maximal Cytoreductive Therapies on Post-treatment Metastases in Pts With mHSPC During Apalutamide Plus ADT Treatment (CHAMPION)

Metastatic Prostate Cancer | Castration-Sensitive Prostate Cancer

China
North Eastern German Society of Gynaecological...
PharmaMar; Frankfurter Institut für Klinische Krebsforschung IKF GmbH

Completed

Comparison of QoL Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer (COMPASS)

Quality of Life | Ovarian Cancer | Recurrent Ovarian Carcinoma

Germany
Massachusetts General Hospital
Johns Hopkins University; M.D. Anderson Cancer Center; National Cancer Institute... and other collaborators

Recruiting

Developing a Test for the Detection of Ovarian Cancer

Ovarian Neoplasms | Fallopian Tube Neoplasms | Stage III Ovarian Cancer AJCC v8 | Stage IIIA Ovarian Cancer AJCC v8 | Stage IIIA1 Ovarian Cancer AJCC v8 | Stage IIIA2 Ovarian Cancer AJCC v8 | Stage IIIB Ovarian Cancer AJCC v8 | Stage IIIC Ovarian Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage... and other conditions

United States
Massachusetts General Hospital
Dana-Farber Cancer Institute; Brigham and Women's Hospital; National Comprehensive...

Completed

Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
University of Washington
National Cancer Institute (NCI)

Completed

Taking Care of Her Program in Patients With Stage III or IV Ovarian Cancer and Spouse Caregivers

Caregiver | Stage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian Cancer

United States
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

Reprab Study: PLD + Trabectedin Rechallenge (MITO36)

Relapsed Ovarian Cancer

Italy
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Ovarian High Grade Serous Adenocarcinoma | Fallopian... and other conditions

United States, Puerto Rico
Centre Leon Berard
Cancer Côte d'or registry; Cancer Calvados registry

Unknown

Optimisation of Disease Management in Patients With Epithelial Ovarian Cancer in France (Ovaire01)

Ovarian Epithelial Cancer

France
Women's Hospital School Of Medicine Zhejiang University

Recruiting

Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Maintenance Treatment: a Multicentre, Open-label, Randomised, Phase 3 Trial

Relapsed Ovarian Cancer

China
Gynecologic Oncology Group
National Cancer Institute (NCI)

Recruiting

Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer

Stage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian Cancer

United States
AstraZeneca
Parexel

Completed

A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body

Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)

Germany
Dana Josephy

Completed

Opportunistic Salpingectomy in Non-gynecological Surgeries

Ovarian Cancer Prevention

Israel
Sheba Medical Center

Unknown

Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Ovarian

Metastatic Ovarian Cancer

Israel
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC

Chemotherapy Effect | Metastatic Prostate Cancer | Hormone Sensitive Prostate Cancer

China
Seoul National University Hospital
Samsung Medical Center; Takeda; Asan Medical Center; Yonsei University

Not yet recruiting

PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer (POLO)

Ovarian Cancer | Epithelial Ovarian Cancer | Ovarian Cancer Stage IV | Ovarian Cancer Stage III
M.D. Anderson Cancer Center
Bristol-Myers Squibb; National Cancer Institute (NCI); Iovance Biotherapeutics

Active, not recruiting

Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma

Malignant Solid Neoplasm | Metastatic Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Platinum-Resistant Ovarian Carcinoma | Metastatic Pancreatic Ductal Adenocarcinoma | Metastatic Ovarian Carcinoma and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Stage III Fallopian Tube Cancer AJCC v7 | Stage III Ovarian Cancer AJCC v6 and v7 | Stage III Primary Peritoneal Cancer AJCC v7 | Stage III Uterine Corpus... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian Carcinoma

United States
University of Utah

Terminated

Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer (ACADEMIC)

Stage IV Prostate Cancer | Metastatic Prostatic Adenocarcinoma | Castration-Sensitive Prostate Carcinoma | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube... and other conditions

United States
AstraZeneca

Recruiting

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents (EvoPAR-PR01)

Metastatic Castration-Sensitive Prostate Cancer

United States, Canada, Spain, United Kingdom, Italy, Australia, Korea, Republic of, Belgium, Germany, Japan, Peru, France, China, India, Taiwan, Thailand, Austria, Brazil, Turkey, Malaysia, Finland, Netherlands, Chile, Hungary, Poland, Sw...
Royal Marsden NHS Foundation Trust
Janssen, LP

Recruiting

Impact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients (ADAPT-P)

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

United Kingdom
Jena University Hospital
Bayer

Recruiting

A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients (ARASAFE)

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Germany
University of Michigan Rogel Cancer Center

Recruiting

Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)

Prostate Cancer | Oligometastatic Disease | Castrate Sensitive Prostate Cancer

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer (CHAARTED)

Metastatic Hormone-sensitive Prostate Cancer

United States
Astellas Pharma China, Inc.

Active, not recruiting

An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) (China ARCHES)

Metastatic Hormone Sensitive Prostate Cancer

China
Sheba Medical Center

Recruiting

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer

Urogenital Neoplasms | Neoplasms, Glandular and Epithelial | Genital Neoplasms, Female | Ovarian Diseases | Ovarian Neoplasms | Carcinoma, Ovarian Epithelial | Neoplasm of Stomach | Ovarian Epithelial Tumor

Israel
VelosBio Inc.

Completed

A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors (MK-2140-002)

Gastric Cancer | Pancreatic Cancer | NSCLC | Platinum-resistant Ovarian Cancer | Triple-negative Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer | Non-squamous Non-small-cell Lung Cancer | Estrogen-receptor-positive Breast Cancer | Progesterone-receptor-positive Breast Cancer | Estrogen-receptor-negative... and other conditions

United States, Canada
CanariaBio Inc.

Terminated

The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer

Ovary Cancer | Ovarian Cancer Stage IV | Neoplasms, Ovarian | Ovarian Cancer Stage III | Ovarian Cancer Recurrent | Cancer of Ovary

United States
Life Research Technologies GmbH

Unknown

Safety of Active Immunotherapy in Subjects With Ovarian Cancer

Ovarian Epithelial Cancer

Austria, Hungary
ARCAGY/ GINECO GROUP
AstraZeneca

Completed

Real-life Data of Olaparib in Relapsed Ovarian Cancers Patients (RETROLA)

Relapsed Ovarian Cancers Patients

France
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy

Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Germ Cell Tumor | Ovarian Sarcoma | Malignant Ovarian Epithelial Tumor | Ovarian Carcinosarcoma | Ovarian Brenner Tumor | Ovarian Mucinous... and other conditions

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission

Stage IIA Fallopian Tube Cancer | Stage IIA Ovarian Cancer | Stage IIB Fallopian Tube Cancer | Stage IIB Ovarian Cancer | Stage IIC Fallopian Tube Cancer | Stage IIC Ovarian Cancer | Stage IIIA Fallopian Tube Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Primary Peritoneal Cancer | Stage IIIB Fallopian... and other conditions

United States
University of Arkansas

Recruiting

A Feasibility Study Evaluating a Role for Maintenance Therapy in Patients With Biochemically Progressive Castration Sensitive Prostate Cancer on Intermittent Androgen Deprivation Therapy

Castration Sensitive Prostate Cancer

United States

Clinical Trials on Platinum Sensitive Relapsed Ovarian Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kazakhstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations